<DOC>
	<DOCNO>NCT02910089</DOCNO>
	<brief_summary>The purpose study evaluate whether combination pharmacist-delivered patient engagement technique improve disease control medication adherence among patient poorly-controlled diabetes compare usual care . These engagement technique include share decision-making brief negotiate interviewing deliver telephonically .</brief_summary>
	<brief_title>ENhancing Outcomes Through Goal Assessment Generating Engagement Diabetes Mellitus</brief_title>
	<detailed_description>The US face grow epidemic type 2 diabetes . Among patient poorly control diabetes , often clear whether problem attributable failure appropriately intensify therapy , poor adherence prescribe medication , unwillingness accept new treatment combination factor . Multi-component pharmacist-delivered intervention , particularly root patient engagement , show effective improve adherence chronic disease medication . Even though share decision make brief negotiated interview complementary patient engagement technique , effectiveness combine 2 intervention approach , especially management diabetes , unknown . In study patient use least one oral hypoglycemic therapy poorly control disease , investigator examine impact share decision make behavioral interview intervention deliver telephonically pharmacist , compare usual care . Briefly , patient allocate intervention mail patient decision aid prime encounter pharmacist . After receive decision aid , patient ask engage provide inform consent least 4 telephonic discussion pharmacist diabetes treatment option , goal , preference , medication adherence , strategy reduce adherence barrier , benefit maintain blood glucose control . The study conduct within large insurer consist 700 patient allocate intervention group control group . Analyses performed intent-to-treat basis . After study completion , investigator also use predictive analytics examine whether treatment response could predict base patient characteristic , sociodemographic , clinical , medication use , motivational characteristic , provide information patient likely benefit intervention .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion : Commerciallyinsured beneficiary Receive medical/prescription drug benefit Horizon On ≥1 one oral hypoglycemic agent Latest HbA1c measurement ≥ 8 % ( within previous 6 month ) Provided phone number Horizon Exclusion : Currently use insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
</DOC>